Asia-Pacific Diagnostic Tests Market Size, Share, Growth Report 2030

Asia-Pacific Diagnostic Tests Market

Asia-Pacific Diagnostic Tests Market By Technology (Next-Generation Sequencing, Immunoassay-Based, Substrate Technology, Spectroscopy-Based, Microfluidics, and Others), By Approach (In-Vitro Diagnostic Instrument, Molecular Diagnostic Instrument, and Point of Care Testing Instrument), By Application (Gynecology, Cardiology, Orthopedics, Oncology, Odontology, Gastroenterology, Neurology, and Others), By End-User (Specialty Clinics, Hospitals & Diagnostic Center, Blood Banks, Homecare, Research Institute, Ambulatory Surgical Centers, and Others), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2023 – 2030

Category: Medical Device Report Format : PDF Pages: 190 Report Code: ZMR-7163 Published Date: Apr-2023 Status : Published

The Asia-Pacific diagnostic tests market size was worth around USD 160.6 Billion in 2022 and is predicted to grow to around USD 351.8 Billion by 2030 with a compound annual growth rate (CAGR) of roughly 10.31% between 2023 and 2030.Asia-Pacific diagnostic tests Industry share By Technology, Approach, Application, End-User, Region

Asia-Pacific Diagnostic Tests Market

Industry Prospective:

The Asia-Pacific diagnostic tests market size was worth around USD 160.6 Billion in 2022 and is predicted to grow to around USD 351.8 Billion by 2030 with a compound annual growth rate (CAGR) of roughly 10.31% between 2023 and 2030.

Asia-Pacific Diagnostic Tests Market SizeRequest Free Sample

The report analyzes the Asia-Pacific diagnostic tests market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the Asia-Pacific diagnostic tests market.

Asia-Pacific Diagnostic Tests Market: Overview

The Asia Pacific diagnostic tests industry refers to the market for medical diagnostic tests in the Asia-Pacific region. It includes a wide range of diagnostic tests, such as clinical laboratory tests, imaging tests, molecular diagnostic tests, and others. The region in a broader sense covers the market in nations such as China, Japan, India, Australia, South Korea, and others. Most of these countries are densely populated and are home to some of the largest consumer groups in terms of population. This is one of the primary reasons why the region is witnessing a surge in quality medical care.

The Asia-Pacific region is highly competitive especially in the healthcare sector and associated industries such as medical devices and equipment due to the presence of numerous regional players along with the growing entry of international players. During the forecast period, the fraternity is expected to witness a steady growth rate but it may face challenges and roadblocks due to several factors.

Key Insights: 

  • As per the analysis shared by our research analyst, the Asia-Pacific diagnostic tests market is estimated to grow annually at a CAGR of around 10.31% over the forecast period (2023-2030)
  • In terms of revenue, the Asia-Pacific diagnostic tests market size was valued at around USD 160.6 billion in 2022 and is predicted to grow to around USD 351.8 billion, by 2030.
  • The Asia Pacific diagnostic tests market is projected to grow at a significant rate due to the growing prevalence of medical conditions
  • Based on technology segmentation, next-generation sequencing was predicted to show maximum market share in the ear 2022
  • Based on approach segmentation, the in-vitro diagnostic instrument was the leading approach in 2022
  • On the basis of region, Japan was the leading revenue generator in 2022

Asia-Pacific Diagnostic Tests MarketRequest Free Sample

Asia-Pacific Diagnostic Tests Market: Growth Drivers

Growing prevalence of medical conditions to propel market growth

The Asia-Pacific diagnostic tests market is projected to witness high growth owing to the increasing prevalence of several types of medical conditions. India and China are home to more than 50% of the global population. This means that the patient pool in these nations is higher than in most of the other countries. Covid-19 infections were a prime example of how easily the virus spread within a few months. For instance, on 7th May 2021, India reported about 414,188 new positive cases of Covid-19 infection, the highest in the country comparing 2020 and 2021 results.

However, it is crucial to note that the healthcare agencies in the region were swift in managing the condition by rolling out vaccine and awareness programs and leveraging digital technology to curb infection spread in the coming years. Similarly, other conditions are rapidly spreading in the Asia-Pacific region which could lead to higher regional growth during the forecast period.

Asia-Pacific Diagnostic Tests Market: Restraints

Limited healthcare infrastructure to restrict market growth

The Asia Pacific diagnostic test industry may witness growth restrictions owing to the limited healthcare infrastructure in some Asian nations. Although several countries are investing heavily in improving healthcare and associated sectors, a major part of the regional economy has to deal with a serious lack of access to basic medical care. For instance, a 2020 report by the World Health Organization (WHO) suggested that nearly 65% of the population in Bangladesh lacks access to primary healthcare services.

Asia-Pacific Diagnostic Tests Market: Opportunities

Growing efforts toward self-dependence to provide growth opportunities

The Asia-Pacific diagnostic test market is expected to benefit from the shifting power dynamics between the Western and Eastern nations across the globe. For instance, several Asian countries are working toward reducing their dependence on other nations such as the US and European countries for the import of advanced diagnostic tools. They are aiming at producing world-class devices domestically by assisting local manufacturers and suppliers. This could assist in higher growth in Asia-Pacific as countries become more self-reliant and reduce their cost of importing goods.

Asia-Pacific Diagnostic Tests Market: Challenges

Large market fragmentation to challenge market growth

The Asia-Pacific diagnostic tests market is highly fragmented due to the presence of several domestic or local stakeholders involved in the process. This acts as a challenge for the industry to manage its revenue as there is a need of streamlining the process. The main concerns lie in market consolidation and competition as fragmentation may lead to similar products circulating in the economy leaving no scope for brand differentiation.

Asia-Pacific Diagnostic Tests Market: Segmentation

The Asia-Pacific diagnostic tests market is segmented based on technology, approach, application, end-user, and region.

Based on technology, the regional market segments are next-generation sequencing, immunoassay-based substrate technology, spectroscopy-based, microfluidics, and others. During the forecast period, the next-generation sequencing (NGS) segment is expected to lead with the highest CAGR. The technology allows for sequencing large amounts of genetic material which is used for the identification of genetic mutations that are related to specific conditions or diseases.

The NGS process is highly cost-effective and has the potential to be used for promoting personalized medical treatment. Other segments such as spectroscopy-based, immunoassay-based substrate technology, and microfluidics also have growth potential. As per official records, China spent nearly USD 19.2 billion on its medical device industry in 2020.

Based on approach, the Asia-Pacific diagnostic tests market segments are in-vitro diagnostic instrument, molecular diagnostic instrument, and point of care testing instrument.

Based on application, the regional market is divided into gynecology, cardiology, orthopedics, oncology, odontology, gastroenterology, neurology, and others. In 2022, the industry witnessed the largest growth in the oncology segment since cancer is a major public health concern in Asian territories. Furthermore, the regional government has accelerated its effort toward spreading public awareness about the conditions and precautionary measures. There have been growing research & development activities to curb the medical issue and improve diagnostic tools for early detection. As per a recent report, South Korea spent around USD 1.7 billion on cancer research between 2005 and 2017. The country’s current population is about 52 million.

Based on end-user, the Asia-Pacific diagnostic tests industry divisions are specialty clinics, hospitals & diagnostic centers, blood banks, homecare, research institute, ambulatory surgical centers, and others.

Recent Developments:

  • In December 2022, PredOmix, an Indian start-up, unveiled OncoVeryx-F. The product is a one-of-its-kind c blood test for detecting cancer. It can detect the deadly disease in its early stages with an accuracy rate of almost 98%. The test is powered using artificial intelligence (AI) and advanced metabolomics technology
  • In June 2022, Apollo Cancer Center, the research wing of the Indian multinational healthcare group, launched a new blood test for the early detection of breast cancer. Experts have suggested that additional complementary tests would be needed to confirm the accuracy of the test. The blood test is called EasyCheck-Breast
  • In August 2021, Berry Oncology, a Berry Genomics subsidiary, accelerated its research on ways to detect liver cancer in its early stages. The screening technique being researched is based on NGS technology

Asia-Pacific Diagnostic Tests Market: Report Scope

Report Attributes Report Details
Report Name Asia-Pacific Diagnostic Tests Market Research Report
Market Size in 2022 USD 160.6 Billion
Market Forecast in 2030 USD 351.8 Billion
Growth Rate CAGR of 10.31%
Number of Pages 190
Key Companies Covered Mindray Medical International Limited, Roche Diagnostics, Bio-Rad Laboratories, Abbott Laboratories, Becton, Dickinson and Company, Siemens Healthineers, F. Hoffmann-La Roche Ltd., Danaher Corporation, QIAGEN N.V., Thermo Fisher Scientific, Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories, Hologic Inc., Ortho Clinical Diagnostics, Cepheid Inc., Luminex Corporation, Meridian Bioscience Inc., Eiken Chemical Co. Ltd., Nihon Kohden Corporation, Alere Inc., BioMérieux SA, DiaSorin S.p.A., Fujirebio Inc., and Grifols S.A.
Segments Covered By Technology, By Approach, By Application, By End-User, By Region,
Regions Covered Asia Pacific (APAC)
Base Year 2022
Historical Year 2017 to 2021
Forecast Year 2023 - 2030
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization

Asia-Pacific Diagnostic Tests Market: Regional Analysis

Japan to witness high growth rate during coming period

The regional Asia-Pacific diagnostic tests market is expected to witness tremendous growth in Japan owing to the robust medical and healthcare infrastructure of the island nation. Several factors have led to the small economy providing excellent medical assistance to its population. One such aspect is the presence of universal healthcare coverage which means that all of the country’s residents have equal access to affordable healthcare irrespective of age, income, and health status. This ensures that patients do not have to worry about the monetary aspects of their health. Japan has always focused on preventive care by conducting regular screenings and check-ups for its residents. This allows them to detect conditions in their early stages letting them provide accurate care. In addition to this, the growing investments toward improving healthcare services could lead to more growth.

Asia-Pacific Diagnostic Tests Market: Competitive Analysis

The Asia-Pacific diagnostic tests market is led by players like:

  • Mindray Medical International Limited
  • Roche Diagnostics
  • Bio-Rad Laboratories
  • Abbott Laboratories
  • Becton
  • Dickinson and Company
  • Siemens Healthineers
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • QIAGEN N.V.
  • Thermo Fisher Scientific
  • Beckman Coulter Inc.
  • Sysmex Corporation
  • Bio-Rad Laboratories
  • Hologic Inc.
  • Ortho Clinical Diagnostics
  • Cepheid Inc.
  • Luminex Corporation
  • Meridian Bioscience Inc.
  • Eiken Chemical Co. Ltd.
  • Nihon Kohden Corporation
  • Alere Inc.
  • BioMérieux SA
  • DiaSorin S.p.A.
  • Fujirebio Inc.
  • Grifols S.A.

The global Asia-Pacific diagnostic tests market is segmented as follows:

By Technology

  • Next-Generation Sequencing
  • Immunoassay-Based
  • Substrate Technology
  • Spectroscopy-Based
  • Microfluidics
  • Others

By Approach

  • In-Vitro Diagnostic Instrument
  • Molecular Diagnostic Instrument
  • Point of Care Testing Instrument

By Application

  • Gynecology
  • Cardiology
  • Orthopedics
  • Oncology
  • Odontology
  • Gastroenterology
  • Neurology
  • Others

By End-User

  • Specialty Clinics
  • Hospitals & Diagnostic Centers
  • Blood Banks
  • Homecare
  • Research Institute
  • Ambulatory Surgical Centers
  • Others

By Region

  • Asia Pacific
    • China
    • Japan
    • India
    • New Zealand
    • Australia
    • South Korea
    • Southeast Asia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Rest of Southeast Asia
    • Rest of Southeast Asia

Table Of Content

Methodology

FrequentlyAsked Questions

 The industry refers to the market for medical diagnostic tests in the Asia-Pacific region. It includes a wide range of diagnostic tests, such as clinical laboratory tests, imaging tests, molecular diagnostic tests, and others.

The Asia-Pacific diagnostic tests market is projected to witness high growth owing to the increasing prevalence of several types of medical conditions. India and China are home to more than 50% of the global population.

According to study, the Asia-Pacific diagnostic tests market size was worth around USD 160.6 billion in 2022 and is predicted to grow to around USD 351.8 billion by 2030.

The CAGR value of the Asia-Pacific diagnostic tests market is expected to be around 10.31% during 2023-2030.

The regional Asia-Pacific diagnostic tests market is expected to witness tremendous growth in Japan owing to the robust medical and healthcare infrastructure of the island nation.

The Asia-Pacific diagnostic tests market is led by players like Mindray Medical International Limited, Roche Diagnostics, Bio-Rad Laboratories, Abbott Laboratories, Becton, Dickinson and Company, Siemens Healthineers, F. Hoffmann-La Roche Ltd., Danaher Corporation, QIAGEN N.V., Thermo Fisher Scientific, Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories, Hologic Inc., Ortho Clinical Diagnostics, Cepheid Inc., Luminex Corporation, Meridian Bioscience Inc., Eiken Chemical Co. Ltd., Nihon Kohden Corporation, Alere Inc., BioMérieux SA, DiaSorin S.p.A., Fujirebio Inc., and Grifols S.A.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed